Cube Labs S p A : SpA and FTherapeutics Announce Collaboration Agreement to Accelerate Early-Stage Drug Discovery

Cube Labs SpA and FTherapeutics Announce Collaboration Agreement to Accelerate Early-Stage Drug Discovery

• Post author:Admin
• Post published:12/04/2024
• Post category:News

Rome and Madrid, 12 aprile 2024 - Cube Labs S.p.A, a life-sciences venture builder based in Italy and listed on the Euronext Growth Milan market, Professional segment, and FTherapeutics, a cluster of companies in Spain, focused on venture drug discovery consulting, today announced a strategic collaboration agreement.

Through this agreement, FTherapeutics, along with its cluster companies Synthelia Organics, a provider of medicinal chemistry and synthesis solutions for the pharmaceutical and biotech industries, and Nostrum Biodiscovery, a company specializing in AI-powered biotechnology solutions for drug discovery, will collaborate with Cube Labs to advance early-stage drug discovery and development projects.

This collaboration will leverage the complementary strengths of both parties. Cube Labs brings its expertise in identifying and building promising healthcare technology companies from the ground up. FTherapeutics and its cluster companies contribute their experience in drug discovery, custom synthesis, route optimization, and artificial intelligence.

"We are excited to partner with FTherapeutics and its cluster companies," said Filippo Surace, CEO of Cube Labs SpA. "This collaboration will enable us to provide even greater value to our portfolio companies and accelerate the development of innovative new drugs."

"This agreement is a significant step forward for FTherapeutics and our cluster companies," said Rafael Ferritto, Manager of FTherapeutics. "By working together with Cube Labs, we will be able to bring our expertise to bear on a wider range of early-stage drug discovery projects."

Cube Labs

Cube Labs is an Italian venture builder in the healthcare technology sector created to bridge the gap between excellent academic science and the commercial Life Science market. Cube Labs creates new companies based on promising R&D activities and promotes innovation to transform pioneering science into healthcare solutions. Through its international network, Cube Labs collaborates with communities interested in innovation to improve patient outcomes and accelerate the global transition toward optimal health. Cube Labs S.p.A. is listed on Euronext Growth Milan, Professional segment.

For further information, please visit the website: www.cube-labs.com

Cube Labs
Global Media Contact
Isil Guney
Tel: [phone]
E-mail: [e-mail]

Ufficio Stampa Italia di Cube Labs
Matteo Steinbach
Cell. [phone]
E-mail: [e-mail]

Federico Ziglioli
Cell. [phone]
E-mail: [e-mail]

FTherapeutics
FTherapeutics is a company focused on venture drug discovery consulting, offering expert analysis of therapeutic assets via its FTasset_360 and FTexecute platforms.

For further information, please visit the website: https://www.ftherapeutics.net/home.

Contacts
Rafael Ferritto Crespo: [e-mail]

You Might Also Like

The great potentiality of Adamas Biotech, a new startup of Cube Labs 08/05/2018 Nature, International Jurnal of Science, highlights the scientific research on the beneficial properties of green tea and the anti-cancer effects of EGC catechins carried out by Prof. Bettuzzi. 12/04/2019 Cube Labs lands in Russia 17/09/2018